An open platform for time-critical workflows

Major biopharmaceutical companies and service providers utilize the Gyros immunoassay platform to boost therapeutic and vaccine development processes. The platform ensures a rapid time to results enabling confident, data-driven decisions and helps to meet increasing regulatory demands

Compatible with any immunoassay design, this open platform enables immunoassays to be run, unattended, at nanoliter scale, significantly increasing productivity and efficiency.

New assays are developed in days, rather than the weeks required for conventional approaches. Established assays are readily transferred into the Gyros platform.

As well as minimizing the consumption of samples and reagents, working at nanoliter scale brings significant advantages to assay performance.

Immunoassays at nanoliter scale within a Bioaffy CD

Fully controlled by the Gyrolab xP workstation, Bioaffy CDs process hundreds of samples in parallel under uniform conditions. Each sample is moves rapidly through the integrated steps of the immunoassay, reducing the risk of matrix effects and shortening analysis time.

The CDs available provide a broad dynamic range, from picogram to milligram, minimizing the need for sample dilutions and so lowering sample repeat rates and reducing potential errors that could compromise data quality.

Rexxip buffers, compatible with a variety of molecules with different analytical properties, save time in assay development and help to achieve top immunoassay performance.

The automated, operator-independent, process ensures that transfer of established assays within or between sites is a seamless, rapid and highly efficient process.